Page last updated: 2024-10-27

fluorouracil and Proliferative Vitreoretinopathy

fluorouracil has been researched along with Proliferative Vitreoretinopathy in 28 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"To determine the efficacy of a combination of 5-fluorouracil and low-molecular-weight heparin (LMWH) to improve the outcome of surgery for established proliferative vitreoretinopathy (PVR)."9.11A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Groenewald, C; Wong, D, 2004)
"To assess the safety and efficacy of adjuvant combination therapy using 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of proliferative vitreoretinopathy (PVR) after vitrectomy and retinal reattachment surgery."9.09Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Khaw, PT; Kon, CH; Wong, D, 2001)
"To evaluate the efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy (PVR)."7.73[Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy]. ( Bi, HS; Cui, Y; Wang, XR; Xie, XF; Zhang, JH, 2006)
"Three new N(1)-alkylcarbonyl-5-fluorouracil derivatives that are prodrugs of 5-fluorouracil (FU), one of them being a co-drug FU-retinoic acid (RA), were studied as potentially effective drugs against postsurgical proliferative vitreoretinopathy (PVR)."7.72Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: formulation in silicone oil and in vitro release of fluorouracil. ( Jolimaître, P; Malet-Martino, M; Martino, R, 2003)
"To determine the potential of an intravitreal sustained release naproxen and 5-fluorouracil (NA/5-FU) codrug for the treatment of experimental proliferative vitreoretinopathy (PVR) in a model for trauma associated tractional retinal detachment (TRD)."7.72An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. ( Ashton, P; Cardillo, JA; Costa, RA; Farah, ME; Jorge, R; Kuppermann, B; Melo, LA; Mitre, J; Morales, PH, 2004)
"To determine the efficacy and pharmacokinetics of an intravitreal sustained-release triamcinolone acetonide and 5-fluorouracil (TA/5-FU) codrug in the treatment of experimental proliferative vitreoretinopathy (PVR)."7.70An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. ( Ashton, P; Chen, SN; Guo, H; Hainsworth, DP; Jaffe, GJ; Khawly, JA; Yang, CS, 1998)
"To determine the efficacy of a combination of 5-fluorouracil and low-molecular-weight heparin (LMWH) to improve the outcome of surgery for established proliferative vitreoretinopathy (PVR)."5.11A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Groenewald, C; Wong, D, 2004)
"To study the safety and efficacy of adjuvant combination therapy using 5-fluorouracil and heparin for prevention of proliferative vitreoretinopathy (PVR) during vitrectomy for retinal detachment surgery."5.11[Prevention of proliferative vitreoretinopathy using 5-FU heparin: clinical tolerance and efficacy]. ( Bonnel, S; Laroche, L; Morel, C; Poisson, F; Sahel, JA; Scheer, S; Touzeau, O, 2005)
"To assess the safety and efficacy of adjuvant combination therapy using 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) for prevention of proliferative vitreoretinopathy (PVR) after vitrectomy and retinal reattachment surgery."5.09Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial. ( Asaria, RH; Aylward, GW; Bunce, C; Charteris, DG; Khaw, PT; Kon, CH; Wong, D, 2001)
"To analyse the cytotoxic and antiproliferative effect of methotrexate (MTX) and fluorouracil (5-FU) in vitro on fibroblasts, retinal pigment epithelial (RPE) and photoreceptor cells as an adjunct for reducing the incidence of proliferative vitreoretinopathy (PVR) after rhegmatogenous retinal detachment surgery."4.02Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells. ( Germann, A; Januschowski, K; Julich-Haertel, H; Rickmann, A; Schulz, A; Szurman, P; von Briesen, H, 2021)
"To evaluate the efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy (PVR)."3.73[Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy]. ( Bi, HS; Cui, Y; Wang, XR; Xie, XF; Zhang, JH, 2006)
"Three new N(1)-alkylcarbonyl-5-fluorouracil derivatives that are prodrugs of 5-fluorouracil (FU), one of them being a co-drug FU-retinoic acid (RA), were studied as potentially effective drugs against postsurgical proliferative vitreoretinopathy (PVR)."3.72Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: formulation in silicone oil and in vitro release of fluorouracil. ( Jolimaître, P; Malet-Martino, M; Martino, R, 2003)
" Macular relocation surgery involved phacoemulsification, vitrectomy, 360 degrees retinotomy, excision of choroidal neovascular membrane, and macular relocation using an infusion of 5-fluorouracil and low molecular weight heparin as adjuvant to prevent proliferative vitreoretinopathy."3.72Case selection in macular relocation surgery for age related macular degeneration. ( Briggs, M; Groenewald, C; Lancaster, E; Lenfestey, P; Li, KK; Lim, KS; Stanga, P; Wong, D, 2004)
"To determine the potential of an intravitreal sustained release naproxen and 5-fluorouracil (NA/5-FU) codrug for the treatment of experimental proliferative vitreoretinopathy (PVR) in a model for trauma associated tractional retinal detachment (TRD)."3.72An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. ( Ashton, P; Cardillo, JA; Costa, RA; Farah, ME; Jorge, R; Kuppermann, B; Melo, LA; Mitre, J; Morales, PH, 2004)
"To determine the efficacy and pharmacokinetics of an intravitreal sustained-release triamcinolone acetonide and 5-fluorouracil (TA/5-FU) codrug in the treatment of experimental proliferative vitreoretinopathy (PVR)."3.70An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. ( Ashton, P; Chen, SN; Guo, H; Hainsworth, DP; Jaffe, GJ; Khawly, JA; Yang, CS, 1998)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (14.29)18.2507
2000's12 (42.86)29.6817
2010's8 (28.57)24.3611
2020's4 (14.29)2.80

Authors

AuthorsStudies
Schaub, F2
Schiller, P2
Hoerster, R2
Kraus, D2
Holz, FG1
Guthoff, R1
Agostini, H1
Spitzer, MS1
Wiedemann, P1
Lommatzsch, A1
Boden, KT1
Dimopoulos, S1
Bemme, S1
Tamm, S1
Maier, M1
Roider, J1
Enders, P1
Altay, L1
Fauser, S2
Kirchhof, B2
van Overdam, KA1
Sebag, J2
Yu, Z1
Ma, S1
Wu, M1
Cui, H1
Wu, R1
Chen, S1
Xu, C1
Lu, X1
Feng, S1
Schulz, A1
Rickmann, A1
Julich-Haertel, H1
Germann, A1
von Briesen, H1
Januschowski, K1
Szurman, P1
Felsch, M1
Zarrouk, M1
Sundaram, V2
Barsam, A2
Virgili, G2
Chiquet, C1
Rouberol, F1
Khan, MA1
Brady, CJ1
Kaiser, RS1
Wickham, L1
Bunce, C3
Wong, D4
Charteris, DG3
Zheng, H1
Wang, Z1
Wang, P1
Liu, Y1
Jiang, Z1
Gao, Q1
Moysidis, SN1
Thanos, A1
Vavvas, DG1
Jolimaître, P1
Malet-Martino, M1
Martino, R1
Stanga, P1
Briggs, M1
Lenfestey, P1
Lancaster, E1
Li, KK1
Lim, KS1
Groenewald, C2
Cardillo, JA1
Farah, ME1
Mitre, J1
Morales, PH1
Costa, RA1
Melo, LA1
Kuppermann, B1
Jorge, R1
Ashton, P3
Aylward, GW3
Asaria, RH2
Scheer, S1
Morel, C1
Poisson, F1
Bonnel, S1
Touzeau, O1
Sahel, JA1
Laroche, L1
Bi, HS1
Cui, Y1
Zhang, JH1
Wang, XR1
Xie, XF1
Creten, O2
Spileers, W2
Stalmans, P2
Borhani, H1
Peyman, GA1
Rahimy, MH1
Thompson, H1
Berger, AS1
Cheng, CK1
Pearson, PA1
Crooks, PA1
Cynkowski, T1
Cynkowska, G1
Jaffe, GJ2
Yang, CS1
Khawly, JA1
Hainsworth, DP1
Chen, SN1
Guo, H1
Kon, CH2
Occleston, NL1
Foss, A1
Sheridan, C1
Khaw, PT2
Tung, IC1
Wu, WC1
Kao, YH1
Chang, YC1
Chung, CH1
Hu, DN1
Allinson, RW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.[NCT02834559]Phase 3326 participants (Actual)Interventional2016-10-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for fluorouracil and Proliferative Vitreoretinopathy

ArticleYear
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
    The Cochrane database of systematic reviews, 2013, Jan-31, Issue:1

    Topics: Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Intravitreal Injections; Postoperative Complica

2013
[Proliferative vitreoretinopathy: prophylactic treatment].
    Journal francais d'ophtalmologie, 2014, Volume: 37, Issue:9

    Topics: Antibiotics, Antineoplastic; Colchicine; Daunorubicin; Fibrinolytic Agents; Fluorouracil; Glucocorti

2014
Clinical management of proliferative vitreoretinopathy: an update.
    Retina (Philadelphia, Pa.), 2015, Volume: 35, Issue:2

    Topics: Anti-Inflammatory Agents; Endotamponade; Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Immuno

2015
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery.
    The Cochrane database of systematic reviews, 2010, Jul-07, Issue:7

    Topics: Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Injections, Intraocular; Postoperative Complica

2010
Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside.
    Mediators of inflammation, 2012, Volume: 2012

    Topics: Animals; Clinical Trials as Topic; Daunorubicin; Fluorouracil; Heparin, Low-Molecular-Weight; Humans

2012

Trials

7 trials available for fluorouracil and Proliferative Vitreoretinopathy

ArticleYear
Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.
    Ophthalmology, 2022, Volume: 129, Issue:10

    Topics: Dalteparin; Double-Blind Method; Fluorouracil; Heparin; Heparin, Low-Molecular-Weight; Humans; Retin

2022
Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141).
    Ophthalmology, 2023, Volume: 130, Issue:6

    Topics: Fluorouracil; Heparin; Humans; Retinal Detachment; Vitreoretinopathy, Proliferative

2023
Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial.
    Trials, 2018, Jul-16, Volume: 19, Issue:1

    Topics: Data Interpretation, Statistical; Double-Blind Method; Endpoint Determination; Fluorouracil; Heparin

2018
Retinal detachment repair by vitrectomy: simplified formulae to estimate the risk of failure.
    The British journal of ophthalmology, 2011, Volume: 95, Issue:9

    Topics: Adult; Aged; Antimetabolites; Female; Fibrinolytic Agents; Fluorouracil; Follow-Up Studies; Heparin,

2011
A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
    Ophthalmology, 2004, Volume: 111, Issue:12

    Topics: Aged; Antimetabolites; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents;

2004
[Prevention of proliferative vitreoretinopathy using 5-FU heparin: clinical tolerance and efficacy].
    Journal francais d'ophtalmologie, 2005, Volume: 28, Issue:7

    Topics: Drug Therapy, Combination; Female; Fluorouracil; Heparin; Humans; Male; Middle Aged; Prospective Stu

2005
Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial.
    Ophthalmology, 2001, Volume: 108, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Female;

2001

Other Studies

16 other studies available for fluorouracil and Proliferative Vitreoretinopathy

ArticleYear
Self-assembling hydrogel loaded with 5-FU PLGA microspheres as a novel vitreous substitute for proliferative vitreoretinopathy.
    Journal of biomedical materials research. Part A, 2020, Volume: 108, Issue:12

    Topics: Animals; Cell Line; Drug Delivery Systems; Fluorouracil; Humans; Hydrogels; Microspheres; Rabbits; V

2020
Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells.
    Acta ophthalmologica, 2021, Volume: 99, Issue:7

    Topics: Apoptosis; Cells, Cultured; Fluorouracil; Humans; Immunosuppressive Agents; Methotrexate; Retinal Pi

2021
Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2012, Volume: 250, Issue:5

    Topics: Animals; Antimetabolites; Aqueous Humor; Biological Availability; Chromatography, High Pressure Liqu

2012
Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: formulation in silicone oil and in vitro release of fluorouracil.
    International journal of pharmaceutics, 2003, Jun-18, Volume: 259, Issue:1-2

    Topics: Chemistry, Pharmaceutical; Drug Stability; Fluorouracil; Kinetics; Magnetic Resonance Spectroscopy;

2003
Case selection in macular relocation surgery for age related macular degeneration.
    The British journal of ophthalmology, 2004, Volume: 88, Issue:2

    Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Choroidal Neovascularization; Fluorouracil; Follow-

2004
An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.
    The British journal of ophthalmology, 2004, Volume: 88, Issue:9

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biodegradation, Environmental; Disease Models, Ani

2004
[Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy].
    [Zhonghua yan ke za zhi] Chinese journal of ophthalmology, 2006, Volume: 42, Issue:1

    Topics: Animals; Antimetabolites; Delayed-Action Preparations; Fluorouracil; Lactates; Microspheres; Rabbits

2006
Systemic absorption of 5-fluorouracil during vitrectomy.
    American journal of ophthalmology, 2006, Volume: 142, Issue:1

    Topics: Absorption; Antimetabolites; beta-Alanine; Fluorouracil; Gas Chromatography-Mass Spectrometry; Human

2006
Systemic resorption of 5-fluorouracil used in infusion fluid during vitrectomy.
    Bulletin de la Societe belge d'ophtalmologie, 2007, Issue:303

    Topics: Absorption; Fluorouracil; Humans; Vitrectomy; Vitreoretinopathy, Proliferative

2007
Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU.
    International ophthalmology, 1995, Volume: 19, Issue:1

    Topics: Animals; Antimetabolites; Biocompatible Materials; Biodegradation, Environmental; Delayed-Action Pre

1995
Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
    Investigative ophthalmology & visual science, 1996, Volume: 37, Issue:11

    Topics: Animals; Antimetabolites; Delayed-Action Preparations; Dexamethasone; Disease Models, Animal; Drug C

1996
An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1998, Volume: 116, Issue:1

    Topics: Animals; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Disease Models, Animal;

1998
Effects of single, short-term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy.
    The British journal of ophthalmology, 1998, Volume: 82, Issue:5

    Topics: Alkylating Agents; Antimetabolites; Cell Culture Techniques; Cell Division; Cell Survival; Collagen;

1998
Shaken not stirred.
    Ophthalmology, 2001, Volume: 108, Issue:7

    Topics: Clinical Trials as Topic; Drug Therapy, Combination; Fluorouracil; Heparin, Low-Molecular-Weight; Hu

2001
The effect of combined 5-fluorouracil and dexamethasone on cultured human retinal pigment epithelial cells.
    The Kaohsiung journal of medical sciences, 2001, Volume: 17, Issue:10

    Topics: Cell Division; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Flu

2001
Adjuvant 5-FU and heparin prevent PVR.
    Ophthalmology, 2002, Volume: 109, Issue:5

    Topics: Chemotherapy, Adjuvant; Drug Therapy, Combination; Fluorouracil; Heparin, Low-Molecular-Weight; Huma

2002